Use of progesterone receptor modulators

• US 20070093548A1
• Filed: 10/12/2006
• Published: 04/26/2007
• Est. Priority Date: 10/25/2005
• Status: Abandoned Application

• Current Assignee: Wyeth (Pfizer Inc.)
• Original Assignee: Wyeth (Pfizer Inc.)
• Inventors: Yang, Cuijian, Mewshaw, Richard, Diffendal, Jason
• Application Number:
  US11/546,785
• Publication Number:
  US 20070093548A1
• Time in Patent Office: Days
• US Class Current: 514/468
• CPC Class Codes: C07D 307/91 Dibenzofurans; Hydrogenated dibenzofurans

Abstract

A progesterone receptor modulator of the structure is provided. Use of compositions containing this compound for contraception, hormone replacement therapy, treating hormone-dependent disease, synchronizing estrus, treating dysmenorrhea, treating dysfunctional uterine bleeding, inducing amenorrhea, or treating symptoms of premenstrual syndrome and premenstrual dysphoric disorder in a mammal are described.

Claims

1. A compound having the structure of formula I, or a pharmaceutically acceptable salt thereof:

wherein R₁ is selected from the group consisting of hydrogen, halogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl;

R₂ is selected from the group consisting of hydroxyl, alkoxy, and substituted alkoxy;

R₃ is selected from the group consisting of hydrogen and halogen; and

R₄ is selected from the group consisting of hydrogen and halogen.

2. The compound according to claim 1, wherein R₁ is selected from the group consisting of hydrogen, halogen, wherein the halogen is bromine, alkyl, wherein the alkyl is C₁-C₆ alkyl, and substituted aryl, wherein the aryl is phenyl.

3. The compound according to claim 1, wherein R₂ is selected from the group consisting of hydroxy and alkoxy, wherein the alkoxy is methoxy.

4. The compound according to claim 1, wherein R₃ is selected from hydrogen and halogen, wherein the halogen is fluorine or bromine.

5. The compound according to claim 1, wherein R₄ is selected from hydrogen and halogen, wherein the halogen is fluorine.

6. The compound according to claim 1, wherein R₁ is an alkyl, wherein the alkyl is a C₃-C₄ alkyl;

R₂ is hydroxy;

R₃ is H; and

R₄ is H.

7. The compound according to claim 1, wherein R₁ is an alkyl, wherein the alkyl is a C₃-C₄ alkyl;

R₂ is methoxy;

R₃ is H; and

R₄ is H.

8. The compound according to claim 1, wherein R₁ is an alkyl having a chiral center.

9. The compound according to claim 8, wherein the chiral center is an in the R-configuration.

10. The compound according to claim 8, wherein the compound is selected from the group consisting of:

7-methoxydibenzo[b,d]furan-2-carbonitrile;

7-hydroxydibenzo[b,d]furan-2-carbonitrile;

6-bromo-8-fluoro-7-hydroxydibenzo[b,d]furan-2-carbonitrile;

8-fluoro-7-hydroxy-6-(2-methylphenyl)dibenzo[b,d]furan-2-carbonitrile;

6-(2-chlorophenyl)-8-fluoro-7-hydroxydibenzo[b,d]furan-2-carbonitrile;

8-fluoro-7-hydroxydibenzo[b,d]furan-2-carbonitrile;

8-fluoro-7-methoxydibenzo[b,d]furan-2-carbonitrile;

8-fluoro-6-(2-fluorophenyl)-7-hydroxydibenzo[b,d]furan-2-carbonitrile;

6-isopropyl-7-methoxydibenzo[b,d]furan-2-carbonitrile;

7-hydroxy-6-isopropyldibenzo[b,a]furan-2-carbonitrile;

6-cyclopentyl-7-hydroxydibenzo[b,d]furan-2-carbonitrile;

6-sec-butyl-7-methoxydibenzo[b,d]furan-2-carbonitrile;

6-sec-butyl-7-hydroxydibenzo[b,d]furan-2-carbonitrile;

(+)-6-sec-butyl-7-hydroxydibenzo[b,d]furan-2-carbonitrile;

(−

)-6-sec-butyl-7-hydroxydibenzo[b,d]furan-2-carbonitrile;

(+)-6-sec-butyl-7-methoxydibenzo[b,d]furan-2-carbonitrile;

(−

)-6-sec-butyl-7-methoxydibenzo[b,d]furan-2-carbonitrile;

and salts thereof.

11. A pharmaceutical composition comprising a compound according to claim 1.

12. A method of inducing contraception, hormone replacement therapy, treating hormone-dependent disease, synchronizing estrus, treating dysmenorrhea, treating dysfunctional uterine bleeding, inducing amenorrhea, or treating symptoms of premenstrual syndrome and premenstrual dysphoric disorder in a mammal,

the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of claim 1.

13. The method according to claim 12, wherein the compound is administered to induce contraception.

14. The method according to claim 12, wherein the compound is administered for hormone replacement therapy.

15. The method according to claim 12, wherein the compound is administered for treating hormone-dependent disease.

16. The method of claim 15, wherein the hormone-dependent disease is selected from the group consisting of uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy;

leiomyoma/fibroids, hormone dependent tumors, carcinomas and adenocarcinomas of the endometrium, colon, prostate, pituitary, and meningioma.

17. The method according to claim 16, wherein the hormone dependent cancers are selected from the group consisting of breast cancer and ovarian cancer.

18. The method according to claim 12, wherein the compound is administered for synchronizing estrus.

19. The method according to claim 12, wherein the compound is administered for treating dysmenorrhea.

20. The method according to claim 12, wherein the method is for treating dysfunctional uterine bleeding.

21. The method according to claim 12, wherein the method is for inducing amenorrhea.

22. The method according to claim 12, wherein the method is for treating symptoms of premenstrual syndrome and premenstrual dysphoric disorder in a mammal.

23. The method according to claim 12, wherein the method is for treating cycle-related symptoms.

24. The method according to claim 23, wherein said symptoms are psychological.

25. The method according to claim 24, wherein said psychological symptoms include mood changes, irritability, anxiety, lack of concentration, or decrease in sexual desire.

26. The method according to claim 23, wherein said symptoms are physical.

27. The method according to claim 26, wherein said physical symptoms include breast tenderness, bloating, fatigue, or food cravings.

28. A contraception regimen which comprises administering to a female of child bearing age for 28 consecutive days:

a) a first phase of from 14 to 24 daily dosage units of a progestational agent equal in progestational activity to about 35 to about 100 μ

g levonorgestrel;

b) a second phase of from 1 to 11 daily dosage units, at a daily dosage of from about 2 to 200 mg, of a compound according to claim 1;

and

c) optionally, a third phase of daily dosage units of an orally and pharmaceutically acceptable placebo for the remaining days of the 28 consecutive days in which no antiprogestin, progestin or estrogen is administered;

wherein the total daily dosage units of the first, second and third phases equals 28.